Publication list
2023
Somodi, L.,
Horváth, E.,
Bárdos, H.,
Baráth, B.,
Pethő, D.,
Katona, É.,
Balla, J.,
Mutch, N.,
Muszbek, L.:
Cellular FXIII in Human Macrophage-Derived Foam Cells.
Int. J. Mol. Sci. 24 (5), 1-12, 2023.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
2022
Székely, E.,
Orbán-Kálmándi, R.,
Szegedi, I.,
Katona, É.,
Baráth, B.,
Czuriga-Kovács, K.,
Lóczi, L.,
Molnárné Vasas, N.,
Fekete, I.,
Fekete, K.,
Berényi, E.,
Oláh, L.,
Csiba, L.,
Bagoly, Z.:
Low [alfa]2-Plasmin Inhibitor Antigen Levels on Admission Are Associated With More Severe Stroke and Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis.
Front. Cardiovasc. Med. 9 1-14, 2022.
Journal metrics:
Q1 Cardiology and Cardiovascular Medicine
2021
Baráth, B.,
Kissné Bogáti, R.,
Miklós, T.,
Kállai, J.,
Mezei, Z.,
Bereczky, Z.,
Muszbek, L.,
Katona, É.:
Effect of [alfa]2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Thromb. Res. 203 110-116, 2021.
Bagoly, Z.,
Baráth, B.,
Orbán-Kálmándi, R.,
Szegedi, I.,
Kissné Bogáti, R.,
Sarkady, F.,
Csiba, L.,
Katona, É.:
Incorporation of [alfa]2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients.
Biomolecules. 11 (3), 1-13, 2021.
Journal metrics:
Q2 Biochemistry
Q2 Molecular Biology
2020
Ząbczyk, M.,
Natorska, J.,
Bagoly, Z.,
Sarkady, F.,
Baráth, B.,
Katona, É.,
Bryk, A.,
Zettl, K.,
Wisniewski, J.,
Undas, A.:
Plasma fibrin clots of pulmonary embolism patients present increased amounts of factor XIII and alpha2-antiplasmin at 3 months' anticoagulation since the acute phase.
J. Physiol. Pharmacol. 71 (4), 519-524, 2020.
Journal metrics:
Q2 Medicine (miscellaneous)
Q2 Pharmacology
Q2 Physiology
Bryk, A.,
Siudut, J.,
Broniatowska, E.,
Bagoly, Z.,
Baráth, B.,
Katona, É.,
Undas, A.:
Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Thromb. Res. 185 88-62, 2020.
2018
Baráth, B.,
Bagoly, Z.,
Szegedi, I.,
Orbán-Kálmándi, R.,
Csiba, L.,
Katona, É.:
Incorporation of Alpha-2-Plasmin Inhibitor into Fibrin Clots and Its Association with the Clinical Outcome of Acute Ischemic Stroke Patients Receiving Thrombolytic Therapy.
Proceedings. 2 (9), 101-102, 2018.
Bagoly, Z.,
Baráth, B.,
Szegedi, I.,
Orbán-Kálmándi, R.,
Csiba, L.,
Katona, É.:
The Effect of Factor XIII Levels on the Incorporation of [alfa]2-plasmin Inhibitor into Fibrin Clots: association with the Therapeutic Outcome of Acute Ischemic Stroke Patients.
Res. Pract. Thromb. Haemost. 2 198-198, 2018.
updated: 2024-10-06, 02:08
